Jazz Pharmaceuticals has agreed to pay $935m for Chimerix, which focuses on the development of dordaviprone, a treatment for the rare brain tumour H3 K27M-mutant diffuse glioma. With Phase 2 results indicating positive effects from its use, Chimerix is seeking accelerated approval for the new formulation. FDA acceptance of the application has resulted in a provisional 18 August decision.
Developer guilty of using kill switch to sabotage employer’s systems
A software developer, Davis Lu, has been found guilty of sabotaging his former employer’s systems by installing custom malware and a “kill switch”. After being
